Exelixis | EXEL - Gross Profit On Sales

Stock Price
43.93
Daily Change
1.56 3.68%
Monthly
-4.89%
Yearly
31.21%
Q1 Forecast
40.09

Exelixis reported $579.18M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 256.99M 13.15M Sep/2025
Agios Pharmaceuticals USD 11.2M 448K Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 406M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Cytokinetics USD 1.94M 64.83M Sep/2025
Eisai JPY 151.84B 8.21B Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Exelixis USD 579.18M 30.39M Sep/2025
Genmab DKK 868M 195M Jun/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.27B 130.22M Sep/2025
Ionis Pharmaceuticals USD 155M 293M Sep/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 809M 791M Sep/2025
Neurocrine Biosciences USD 780.9M 104.7M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Sanofi EUR 8.45B 3.02B Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
Ultragenyx Pharmaceutical USD 131.94M 11.55M Sep/2025
Xencor USD 21M 22.61M Sep/2025